Incepta launches new drug for fatty liver and MASH

FE Team | Published: December 02, 2025 23:54:23

Liver diseases, particularly fatty liver and metabolic dysfunction associated steatohepatitis (MASH), are emerging as leading health challenges in Bangladesh.
Incepta Pharmaceuticals has introduced a new medicine, Frehepta (generic name: Resmetirom), for the treatment of fatty liver and MASH. This is the first time the drug has been made available in Bangladesh, says a press statement.
Globally, Resmetirom has shown promising results in managing fatty liver and MASH, including a significant reduction in liver fat, improvement in fibrosis markers, and a lower risk of adverse effects.
Incepta Pharmaceuticals has introduced Frehepta at an affordable price, emphasising that it should only be used under the prescription of a registered physician.